Clinical results of proton beam therapy for skull base chordoma

Igaki, Hiroshi; Tokuuye, Koichi; Okumura, Toshiyuki; Sugahara, Shinji; Kagei, Kenji; Hata, Masaharu; Ohara, Kiyoshi; Hashimoto, Takayuki; Tsuboi, Koji; Takano, Shingo; Matsumura, Akira; Akine, Yasuyuki

doi:10.1016/j.ijrobp.2004.05.064

Cited by 155 publications

(74 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45 Those results are in keeping with other published series. 16,46,47 Thus, it appears that the risk of local recurrence and subsequent death is more neutral with regard to sex than initially assumed. In the previous SEER analysis, the impact on outcomes from various clinical and therapeutic characteristics was assessed.…”

Section: Sex and Survivalmentioning

confidence: 99%

Incidence and relative survival of chordomas

Smoll

Gautschi

Radovanović

et al. 2013

Cancer

168

View full text Add to dashboard Cite

BACKGROUND: Chordomas are rare bone tumors arising from remnants of the embryonic notochord. METHODS: Data for this study were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute to calculate the incidence, relative survival (RS), and standardized mortality ratio (SMR) of patients diagnosed with intracranial and extracranial chordomas and to assess the effects of age and sex on this disease. RESULTS: The overall incidence of extracranial and intracranial chordomas was 8.4 per 10 million population. The median overall survival of patients with chordoma patients was 7.7 years. The median survival was 7.7 years for male patients and 7.8 years for female patients. Younger patients (aged <40 years) survived longer compared with older patients (10-year RS, 68% vs 43%). The estimated age-standardized 5-year, 10-year, and 20-year RS rates was 72%, 48%, and 31%, respectively. The SMR in the overall cohort was 4.6 (95% confidence interval, 4.22-5.0) or 21.0 (95% confidence interval, 16.6-27.2) in young adult patients and 3.0 (95% confidence interval, 2.6-3.4) in elderly patients. CONCLUSIONS: The elderly had a more aggressive form of this disease; and, other than the incidence, sex did not influence outcome in this disease. The study of chordomas presents a good case for the contribution that the SMR can have on measuring the impact of a disease on a population of patients. Although the younger population has better survival rates, the impact (SMR) in the younger age groups is much higher than in older populations.

show abstract

Section: Sex and Survivalmentioning

confidence: 99%

Incidence and relative survival of chordomas

Smoll

Gautschi

Radovanović

et al. 2013

Cancer

168

View full text Add to dashboard Cite

show abstract

“…[45][46][47][48]51,53 Pediatric CHs seem to fare better compared with their adult counterparts: 60-100% and 80-100%, respectively. 13,30,50,54,55 Nonetheless, younger children were frequently excluded in earlier series dealing with protons (since they require special attention, such as general anesthesia).…”

Section: Review Of Literaturementioning

confidence: 99%

“…45 This favorable outcome has been reproduced by multiple teams in US, Europe and Japan. [46][47][48] Doses were progressively upgraded to 75 Gy (EBR) (Gy (EBR) = physical dose × an estimated mean 1.1 RBE) and more, conventionally fractionated, at the price of an acceptable toxicity. Recently, carbon ions have also been advocated in place of protons.…”

Section: Review Of Literaturementioning

confidence: 99%

Reprint of “Chordoma in children: Case-report and review of literature”

Habrand

Datchary

Bolle

et al. 2016

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Sarcoma Protontherapy Children a b s t r a c tWe report an exceptional case of a very late local failure in a 9-year-old boy presenting with a chordoma of the cranio-cervical junction. The child was initially treated with a combination of surgical resection followed by high dose photon-proton radiation therapy. This aggressive therapy allowed a 9-year remission with minimal side-effects. Unfortunately, he subsequently presented with a local failure managed with a second full-dose course of protons. The child died one year later from local bleeding of unclear etiology.© 2015 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved. IntroductionChordomas ( with the brachyury gene, a gene involved in the notochord development. 5,6 In the adults, they are located typically in the sacrococcygeal (SC) (50%), the intra cranial (IC), at the skull base (SB) (35%), and the intermediate spinal (S) regions (15%). Only 5% of cases have been described in the pediatric age, with unclear specificities concerning presentation, and outcome. We report in this paper a clinical case of skull base CH http://dx

show abstract

“…A few articles describe also the use of a mixed proton/photon beam (Table 5 [9][10][11][91][92][93][94][95][96][97][98][99][100][101][102]. From the methodological point of view, the large majority of the studies are retrospective and may include different tumour types: chordoma, chondrosarcoma, and meningioma of grade I-III.…”

Section: Proton Radiotherapymentioning

confidence: 99%

Review of photon and proton radiotherapy for skull base tumours

Fossati

Vavassori²,

Deantonio

et al. 2016

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

a b s t r a c tAn extremely large variety of benign and malignant tumours occur at skull base; these tumour lesions are in the proximity to structures deputed to relevant physiologic functions, limiting extensive surgical approaches to this body district. Most recent progresses of surgery and radiotherapy have allowed to improve local control with acceptable rates of side effects. Various photon radiotherapy techniques are employed, including 3-dimensional conformal radiotherapy, intensity modulated radiotherapy (IMRT), stereotactic radiotherapy (SRT) and brachytherapy that is manly limited to the treatment of primary or recurrent nasopharyngeal carcinoma. Proton beam radiotherapy is also extensively used thanks to its physical characteristics. Our review, focusing in particular on meningioma, chordoma, and chondrosarcoma, suggests that proton therapy plays a major role in the treatment of malignant tumours whereas photon therapy still plays a relevant role in the treatment of benign tumour lesions.

show abstract

Clinical results of proton beam therapy for skull base chordoma

Cited by 155 publications

References 31 publications

Incidence and relative survival of chordomas

Incidence and relative survival of chordomas

Reprint of “Chordoma in children: Case-report and review of literature”

Review of photon and proton radiotherapy for skull base tumours

Contact Info

Product

Resources

About